Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR EMA Recommends Extension of Indications for Crizotinib September 23, 2022 The team tackling the serious side effects of cancer treatment in... August 19, 2020 Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 COVID-19: “The really hard part is we know what needs to... July 7, 2020 Load more HOT NEWS Women at High Risk of Breast Cancer Find it Hard to... Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk How to Keep Your Loved One With Cancer Safe From Infection...
